Canada & Optimi Health

Canada: Canada's regulatory environment, where ibogaine is not a controlled substance and Optimi Health has GMP infrastructure and Canada — Health Canada licensing, positions it as an advantageous base for ibogaine manufacture and supply.

Optimi Health: Optimi Health has secured ibogaine supply and is commencing development of finished drug products, positioning itself as a key supplier in the emerging psychedelic therapy market.

Canada: Canada is the country where Optimi Health manufactures its psilocybin and MDMA products at its GMP facility and from where it exports these products internationally.

Optimi Health: Optimi Health completed its third commercial shipment of psilocybin to Australia, expanding its market presence and generating recurring revenue from the sale of its psychedelic drug products for medical use.

Canada: Canada is the location of Optimi Health's GMP facility where the psilocybin products are manufactured and from where Canada — Health Canada issues export authorizations.

Optimi Health: Optimi Health completed its first export of psilocybin to the United Kingdom for a Phase 2 clinical trial, expanding its international market reach and solidifying its position as a vertically integrated GMP supplier of psychedelic drug products. It also completed a GMP production run of 5mg psilocybin capsules, with some earmarked for clinical research in the United States and Europe.

Optimi Health: Optimi Health Corp. has launched new microdose psilocybin products, expanding its product range and market reach for clinical research and therapeutic programs internationally. This development is expected to positively impact the company's revenue and market position.